Product Description
Ferric derisomaltose injection is an iron replacement product that is used to treat iron deficiency anemia (not enough iron in the blood) in patients with non-dialysis dependent chronic kidney disease (CKD), and in patients who are taking iron supplements that did not work well. (Sourced from: https://www.mayoclinic.org/drugs-supplements/ferric-derisomaltose-intravenous-route/description/drg-20481648)
Mechanisms of Action: Iron Replacer
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Belgium | Brazil | Bulgaria | Canada | Denmark | Estonia | Finland | France | Iceland | Italy | Japan | Korea | Lithuania | Malaysia | New Zealand | Norway | Philippines | Poland | Russia | Sweden | United Arab Emirates | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Pharmacosmos
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Anemia, Iron-Deficiency|Heart Failure, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| P-Monofer-PED-01 | P3 |
Recruiting |
Anemia, Iron-Deficiency |
2026-04-30 |
18% |
| CHF-02 | P3 |
Not yet recruiting |
Heart Failure, Chronic |
2027-12-01 |
36% |